Síndrome de Verner-Morrison (VIPoma)

Referências

Principais artigos

Soga J, Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res. 1998 Dec;17(4):389-400. Resumo

Ghaferi AA, Chojnacki KA, Long WD, et al. Pancreatic VIPomas: subject review and one institutional experience. J Gastointest Surg. 2008 Feb;12(2):382-93. Resumo

Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):501-13. Resumo

Artigos de referência

1. Soga J, Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res. 1998 Dec;17(4):389-400. Resumo

2. Camera L, Severino R, Faggiano A, et al. Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma. World J Radiol. 2014 Oct 28;6(10):840-5.Texto completo  Resumo

3. Oberg K, Jelic S; ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii124-30.Texto completo  Resumo

4. Laing E, Kiss N, Michael M, et al. Nutritional complications and the management of patients with gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology. 2020;110(5):430-42.Texto completo  Resumo

5. Friesen S. Update on the diagnosis and treatment of rare neuroendocrine tumors. Surg Clin North Am. 1987 Apr;67(2):379-93. Resumo

6. Ghaferi AA, Chojnacki KA, Long WD, et al. Pancreatic VIPomas: subject review and one institutional experience. J Gastointest Surg. 2008 Feb;12(2):382-93. Resumo

7. Smith SL, Branton SA, Avino AJ, et al. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery. 1998 Dec;124(6):1050-5. Resumo

8. Peng SY, Li JT, Liu YB, et al. Diagnosis and treatment of VIPoma in China: (case report and 31 cases review) diagnosis and treatment of VIPoma. Pancreas. 2004 Jan;28(1):93-7. Resumo

9. Nikou GC, Toubanankis C, Nikolaou P, et al. VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology. 2005 Jul-Aug;52(64):1259-65. Resumo

10. Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007 Dec;14(12):3492-500.Texto completo  Resumo

11. Holst JJ, Fahrenkrug J, Knuhtsen S, et al. Vasoactive intestinal polypeptide (VIP) in the pig pancreas: role of VIPergic nerves in the control of fluid and bicarbonate secretion. Regul Pept. 1984;8:245-59. Resumo

12. Robberecht P, Conlon TP, Gardner JD. Interaction of porcine vasoactive intestinal peptide with dispersed pancreatic acinar cells from the guinea pig: structural requirements for effects of vasoactive intestinal peptide and secretin on cellular adenosine 3':5'-monophosphate. J Biol Chem. 1976;251:4635-9 Resumo

13. Barbezat GO, Grossman MI. Intestinal secretion: stimulation by peptides. Science. 1971;174:422-4. Resumo

14. Fahrenkrug J. Transmitter role of vasoactive intestinal peptide. Pharmacol Toxicol. 1993;72:354-63. Resumo

15. Biancani P, Walsh JH, Behar J. Vasoactive intestinal polypeptide: a neurotransmitter for lower esophageal sphincter relaxation. J Clin Invest. 1984;73:963-7.Texto completo  Resumo

16. Usdin TB, Bonner TI, Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology. 1994;135:2662-80 Resumo

17. Doherty GM. Rare endocrine tumours of the GI tract. Best Prac Res Clin Gastroenterol. 2005 Oct;19(5):807-17. Resumo

18. Rood RP, DeLellis RA, Dayal Y, et al. Pancreatic cholera syndrome due to a vasoactive intestinal polypeptide-producing tumor: further insights into the pathophysiology. Gastroenterology. 1988 Mar;94(3):813-8. Resumo

19. Sadowski SM, Neychev V, Millo C, et al. Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 2016 Feb 20;34(6):588-96.Texto completo  Resumo

20. Modlin IM, Pavel M, Kidd M, et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010 Jan 15;31(2):169-88.Texto completo  Resumo

21. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol. 2001;12 Suppl 2:S111-4. Resumo

22. Maton PN, Gardner JD, Jensen RT. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci. 1989;34(3 suppl):28-39S. Resumo

23. Delaunoit T, Neczyporenko F, Rubin J, et al. Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol. 2008 Feb;103(2):475-83. Resumo

24. Nguyen HN, Backes B, Lammert F, et al. Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options. Dig Dis Sci. 1999 Jun;44(6):1148-55. Resumo

25. Thompson LA, Kim M, Wenger SD, et al. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors. Ann Pharmacother. 2012 Sep;46(9):1212-9. Resumo

26. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):501-13. Resumo

27. National Institute for Health and Care Excellence. Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease. June 2017 [internet publication].Texto completo

28. Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol. 2007 May;188(5):1201-7.Texto completo  Resumo

29. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008 Sep 1;113(5):921-9. Resumo

30. Johnston PC, Ardill JE, Johnston BT, et al. Vasoactive intestinal polypeptide secreting pancreatic tumour with hepatic metastases: long term survival after orthotopic liver transplantation. Ir J Med Sci. 2010 Sep;179(3):439-41. Resumo

31. Máthé Z, Tagkalos E, Paul A, et al. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. Transplantation. 2011 Mar 15;91(5):575-82. Resumo

32. Delpassand ES, Sims-Mourtada J, Saso H, et al. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm. 2008 Jun;23(3):292-300. Resumo

33. Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Nov;21(11):1500-12. Resumo

34. Perry RR, Vinik AI. Clinical review 72: diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab. 1995 Aug;80(8):2273-8.Texto completo  Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal